Vithika Suri

1.9k total citations
40 papers, 350 citations indexed

About

Vithika Suri is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Vithika Suri has authored 40 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hepatology, 32 papers in Epidemiology and 11 papers in Infectious Diseases. Recurrent topics in Vithika Suri's work include Hepatitis C virus research (32 papers), Hepatitis B Virus Studies (29 papers) and Liver Disease Diagnosis and Treatment (20 papers). Vithika Suri is often cited by papers focused on Hepatitis C virus research (32 papers), Hepatitis B Virus Studies (29 papers) and Liver Disease Diagnosis and Treatment (20 papers). Vithika Suri collaborates with scholars based in United States, Spain and Italy. Vithika Suri's co-authors include Anuj Gaggar, Kimberly K. Scarsi, Ingrid Macio, Leslie A. Meyn, Elizabeth E. Krans, Sharon L. Hillier, Catherine A. Chappell, Katherine Bunge, Debra L. Bogen and Brian Kirby and has published in prestigious journals such as Gastroenterology, Clinical Infectious Diseases and Gut.

In The Last Decade

Vithika Suri

36 papers receiving 338 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vithika Suri United States 9 264 263 52 39 30 40 350
Martina Helbig Germany 7 349 1.3× 318 1.2× 40 0.8× 34 0.9× 13 0.4× 11 437
Paola Zuccalà Italy 8 125 0.5× 130 0.5× 77 1.5× 8 0.2× 8 0.3× 13 278
Satomi Iwasaki Japan 13 436 1.7× 458 1.7× 91 1.8× 10 0.3× 8 0.3× 22 519
Taotao Yan China 11 247 0.9× 190 0.7× 42 0.8× 7 0.2× 5 0.2× 31 298
Shujing Song China 9 124 0.5× 93 0.4× 187 3.6× 11 0.3× 6 0.2× 23 326
Zhongping Duan China 10 696 2.6× 639 2.4× 134 2.6× 9 0.2× 5 0.2× 32 744
S Iwasaki Japan 3 266 1.0× 288 1.1× 22 0.4× 4 0.1× 19 0.6× 4 378
Zhongping Duan China 4 420 1.6× 363 1.4× 86 1.7× 10 0.3× 5 0.2× 10 446
Naofumi Ohno Japan 8 398 1.5× 383 1.5× 29 0.6× 4 0.1× 6 0.2× 12 426
Rúbia Anita Ferraz Santana Brazil 9 104 0.4× 81 0.3× 118 2.3× 8 0.2× 12 0.4× 17 235

Countries citing papers authored by Vithika Suri

Since Specialization
Citations

This map shows the geographic impact of Vithika Suri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vithika Suri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vithika Suri more than expected).

Fields of papers citing papers by Vithika Suri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vithika Suri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vithika Suri. The network helps show where Vithika Suri may publish in the future.

Co-authorship network of co-authors of Vithika Suri

This figure shows the co-authorship network connecting the top 25 collaborators of Vithika Suri. A scholar is included among the top collaborators of Vithika Suri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vithika Suri. Vithika Suri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
González‐Peralta, Regino P., Jessica Wen, Winita Hardikar, et al.. (2025). Long-term efficacy and safety of sofosbuvir-based direct-acting antiviral regimens in paediatric patients with hepatitis C virus infection: an international registry study. The Lancet Child & Adolescent Health. 9(4). 248–254. 1 indexed citations
2.
Allweiss, Lena, Vithika Suri, Jeffrey J. Wallin, et al.. (2024). Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies. Journal of Hepatology. 80(6). 882–891. 18 indexed citations
3.
Buti, Marı́a, Heiner Wedemeyer, Soo Aleman, et al.. (2024). Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide. Journal of Hepatology. 82(1). 28–36. 7 indexed citations
4.
Pan, David Z., Cameron M. Soulette, Abhishek Aggarwal, et al.. (2024). Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B. Gut. 74(4). 628–638. 4 indexed citations
5.
6.
Buti, Marı́a, Heiner Wedemeyer, Soo Aleman, et al.. (2023). Treatment with Bulevirtide Improves Patient-reported Outcomes in Patients with Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks. Zeitschrift für Gastroenterologie. 61(1). e47–e47.
7.
Aggarwal, Abhishek, Pamela M. Odorizzi, Jens Brodbeck, et al.. (2022). Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells. JHEP Reports. 5(4). 100664–100664. 17 indexed citations
8.
Buuren, Nicholas van, Ricardo Ramírez, Cameron M. Soulette, et al.. (2022). Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B. JHEP Reports. 4(4). 100449–100449. 37 indexed citations
9.
Hsu, Yao‐Chun, Vithika Suri, Mindie H. Nguyen, et al.. (2022). Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation. Gastroenterology. 162(4). 1160–1170.e1. 46 indexed citations
10.
11.
Va, Isakov, Charlotte Hedskog, Joel O. Wertheim, et al.. (2021). Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. International Journal of Infectious Diseases. 113. 36–42. 6 indexed citations
12.
13.
Chappell, Catherine A., Kimberly K. Scarsi, Brian Kirby, et al.. (2020). Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. The Lancet Microbe. 1(5). e200–e208. 78 indexed citations
14.
15.
Criner, Gerard J., Mi Young Ahn, Gregory Huhn, et al.. (2020). 561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19. Open Forum Infectious Diseases. 7(Supplement_1). S345–S346. 4 indexed citations
16.
17.
18.
19.
20.
Gupta, Ishita, et al.. (2003). Inferior vena cava diameters in pregnant women for prediction of pregnancy‐induced hypertension. International Journal of Gynecology & Obstetrics. 84(2). 164–165. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martina Helbig Breakdown of academic impact, for papers by Paola Zuccalà Breakdown of academic impact, for papers by Satomi Iwasaki Breakdown of academic impact, for papers by Taotao Yan Breakdown of academic impact, for papers by Shujing Song Breakdown of academic impact, for papers by Zhongping Duan Breakdown of academic impact, for papers by S Iwasaki Breakdown of academic impact, for papers by Zhongping Duan Breakdown of academic impact, for papers by Naofumi Ohno Breakdown of academic impact, for papers by Rúbia Anita Ferraz Santana
Rankless by CCL
2026